ANSWER: B

Rationale:

Alpha-CGRP is the neuropeptide at the center of modern migraine pharmacology. It is a 37-amino-acid neuropeptide produced by alternative splicing of the calcitonin gene (CALCA) transcript in pseudounipolar neurons of the trigeminal ganglion (TGG). These are small- to medium-diameter, unmyelinated or thinly myelinated C- and A-delta fibers that send peripheral projections to the meningeal dura mater and large cerebral arteries, and central projections to the trigeminal nucleus caudalis (TNC) in the brainstem. CGRP is stored in dense-core vesicles and released from both peripheral and central terminals upon depolarization. The visual aura this patient experiences reflects cortical spreading depression (CSD), which propagates at 3 to 5 mm per minute across the occipital cortex and activates meningeal trigeminal afferents, driving CGRP release that initiates the headache phase. The seminal demonstration of elevated CGRP in external jugular venous blood ipsilateral to the headache side during spontaneous migraine attacks — with normalization after sumatriptan — established the trigeminovascular hypothesis and provided the rationale for anti-CGRP pharmacotherapy.

• Option A: Option A is incorrect because substance P was investigated as a migraine target but failed as a therapeutic target, and it is not the neuropeptide responsible for the vasodilatory component of migraine; the primary trigeminal neuropeptide of clinical relevance in migraine is alpha-CGRP, not substance P.
• Option C: Option C is incorrect because beta-CGRP is encoded by the CALCB gene and expressed primarily in the enteric nervous system; it is not the isoform released from the trigeminal ganglion during migraine, and there is no established secondary vagal activation pathway linking enteric beta-CGRP to migraine headache.
• Option D: Option D is incorrect because adrenomedullin is a distinct peptide that binds CLR/RAMP2 heterodimers (not RAMP1), and it is not the primary neuropeptide mediating trigeminovascular activation in migraine; the CGRP receptor requires RAMP1, not RAMP2, for CGRP specificity.
• Option E: Option E is incorrect because while VIP is released from sphenopalatine ganglion neurons and contributes to cranial parasympathetic vasodilation in some headache disorders, it is not the primary trigeminal neuropeptide responsible for the vasodilatory and pain-sensitizing component of migraine and is not the target of current migraine-specific pharmacotherapy.

ANSWER: D

Rationale:

The CGRP receptor is pharmacologically unusual in that it is a heterodimeric complex assembled from two distinct proteins: calcitonin receptor-like receptor (CLR), a seven-transmembrane Gs-coupled receptor that cannot reach the plasma membrane without a chaperone, and receptor activity-modifying protein 1 (RAMP1), a single-transmembrane protein that escorts CLR to the cell surface and critically determines its ligand specificity. The identity of the RAMP subunit is the molecular switch that determines receptor pharmacology: CLR paired with RAMP1 constitutes the canonical CGRP receptor, while CLR paired with RAMP2 or RAMP3 forms the adrenomedullin receptor. This RAMP-dependent specificity is the conceptual basis for how erenumab, which binds the CLR/RAMP1 interface, achieves CGRP receptor selectivity without cross-reacting with adrenomedullin receptors.

• Option A: Option A is incorrect because CLR does not form a homodimer, and CGRP receptor specificity is not determined by glycosylation of CLR; it is determined by the identity of the RAMP chaperone protein (RAMP1 for CGRP, RAMP2 or RAMP3 for adrenomedullin).
• Option B: Option B is incorrect because CLR is not a stand-alone single receptor that achieves surface expression through beta-arrestin dimerization; beta-arrestin is a signaling scaffold involved in receptor desensitization and internalization, not a membrane chaperone that replaces RAMP in the CGRP receptor complex.
• Option C: Option C is incorrect on two counts: the CGRP receptor does not involve the calcitonin receptor (CTR), which is a distinct protein, and RAMP2 paired with CLR forms the adrenomedullin receptor, not the CGRP receptor; RAMP1 is the subunit that confers CGRP selectivity.
• Option E: Option E is incorrect because RAMP3 paired with CLR forms the adrenomedullin 2 receptor, not the CGRP receptor; RAMP3 does not confer CGRP specificity, and RAMP1 — not RAMP3 — is the obligate subunit for the canonical CGRP receptor.

ANSWER: A

Rationale:

Upon CGRP binding to the CLR/RAMP1 heterodimer, the receptor couples to the stimulatory G protein Gs, which activates adenylyl cyclase to generate cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets in vascular smooth muscle cells, including myosin light chain kinase (reducing its activity) and ATP-sensitive potassium (KATP) channels (increasing potassium efflux and hyperpolarizing the membrane). The net result is smooth muscle relaxation and sustained vasodilation of cranial dural vessels, which is the primary peripheral mechanism contributing to migraine pain. CGRP also signals in trigeminal ganglion neurons and at the trigeminal nucleus caudalis, where cAMP-mediated mechanisms sensitize nociceptors and potentiate glutamate signaling, contributing to central sensitization and the allodynia this patient experiences.

• Option B: Option B is incorrect because CGRP signals through Gs and cAMP, not through Gq and the phospholipase C/IP3/DAG pathway; the Gq/IP3 pathway releases intracellular calcium and activates myosin light chain kinase to produce contraction, the opposite of CGRP's vasodilatory effect.
• Option C: Option C is incorrect because CGRP activates Gs (stimulatory), not Gi (inhibitory); Gi-coupled receptors inhibit adenylyl cyclase and reduce cAMP, and the Rho-kinase pathway described produces vasoconstriction — again the opposite of CGRP's effect.
• Option D: Option D is incorrect because Gs does not directly open voltage-gated calcium channels; the Gs/cAMP/PKA cascade phosphorylates KATP channels and myosin light chain kinase, and the net effect is vasodilation, not the initial contraction followed by reflex vasodilation described; furthermore, calcium channel opening would produce contraction, not relaxation.
• Option E: Option E is incorrect because G12/13-RhoA-ROCK signaling inhibits myosin light chain phosphatase, thereby maintaining smooth muscle phosphorylation and contraction — this is a vasoconstrictor pathway used by angiotensin II and endothelin, not the vasodilatory Gs/cAMP pathway through which CGRP acts.

ANSWER: C

Rationale:

The fundamental pharmacological distinction between triptans and gepants with respect to cardiovascular safety is receptor mechanism. Triptans (sumatriptan, rizatriptan, eletriptan, and others) are 5-HT1B/1D receptor agonists. Activation of 5-HT1B receptors on vascular smooth muscle produces direct coronary and cerebral vasoconstriction, which is therapeutically useful in dilated intracranial vessels during migraine but creates ischemic risk in patients with coronary artery disease whose vessels are already compromised by atherosclerotic plaque and reduced vasodilatory reserve. This is the basis for the contraindication of all triptans in ischemic heart disease, uncontrolled hypertension, stroke, and peripheral vascular disease. Gepants, by contrast, are competitive antagonists at the CLR/RAMP1 CGRP receptor and produce no vasoconstriction whatsoever: they block the vasodilatory effect of CGRP without activating any vasoconstrictor pathway, making them safe to use in patients with cardiovascular disease who are excluded from triptan therapy. This opens migraine pharmacotherapy to a large population of patients with cardiovascular comorbidities.

• Option A: Option A is incorrect because triptans are not adenylyl cyclase inhibitors, and gepants do not stimulate adenylyl cyclase; triptans act through 5-HT1B/1D receptors, and gepants are receptor antagonists that block CGRP signaling without directly modulating cAMP production.
• Option B: Option B is incorrect because while telcagepant (a first-generation gepant) was discontinued for hepatotoxicity, this was at doses required for prevention and is not the reason triptans are contraindicated in coronary artery disease; the coronary risk of triptans is mechanistic (5-HT1B-mediated vasoconstriction), not related to drug interactions with antiplatelet agents.
• Option D: Option D is incorrect because triptans are not MAO substrates that produce toxic coronary endothelial intermediates; sumatriptan is in fact metabolized by MAO-A in the liver, but this is a hepatic metabolic pathway, not a coronary one, and the mechanism of triptan cardiac risk is 5-HT1B-mediated vasoconstriction, not metabolic toxicity.
• Option E: Option E is incorrect because triptans do not selectively spare 5-HT1D while activating 5-HT1B; all approved triptans are dual 5-HT1B/1D agonists, and gepants are CGRP receptor antagonists with no 5-HT receptor activity whatsoever — they do not selectively block any serotonin receptor subtype.

ANSWER: E

Rationale:

Erenumab is the only approved anti-CGRP monoclonal antibody that targets the receptor rather than the peptide. Specifically, erenumab binds to the extracellular domain formed at the CLR/RAMP1 interface — an epitope unique to the assembled heterodimer — and overlaps with the CGRP peptide binding domain, explaining its competitive antagonism at the receptor level. Fremanezumab, galcanezumab, and eptinezumab all target the CGRP ligand (the peptide itself), preventing it from reaching the receptor. This receptor-versus-ligand distinction has a clinically important implication: patients who fail one mechanism may respond to the other, because the escape mechanisms differ; a patient who develops pharmacodynamic tolerance to erenumab through upregulation of downstream receptor signaling might still respond to ligand-targeted antibodies that reduce the CGRP signal upstream, and vice versa.

• Option A: Option A is incorrect because none of the four approved anti-CGRP monoclonal antibodies crosses the blood-brain barrier to any clinically meaningful degree; all are approximately 147 to 150 kDa proteins that are excluded from the CNS under normal conditions, and their therapeutic efficacy is mediated through peripheral CGRP blockade at meningeal vessels and the trigeminal ganglion (which lies outside the blood-brain barrier).
• Option B: Option B is incorrect because erenumab is a conventional protein-based fully human monoclonal antibody (IgG2 subclass), not a synthetic peptide; no approved anti-CGRP therapy operates at the level of CALCA gene transcription.
• Option C: Option C is incorrect because erenumab is a monospecific antibody targeting only the CGRP receptor, not a bispecific antibody; it does not simultaneously target the CGRP ligand, and none of the four approved anti-CGRP antibodies has a bispecific structure.
• Option D: Option D is incorrect because erenumab is dosed monthly (70 or 140 mg subcutaneously once monthly), not quarterly; the quarterly dosing schedule belongs to fremanezumab (675 mg quarterly as an alternative to 225 mg monthly) and eptinezumab (100 or 300 mg IV quarterly).

ANSWER: B

Rationale:

Ubrogepant undergoes extensive first-pass metabolism by CYP3A4, producing an oral bioavailability of only approximately 7 percent under normal conditions. Clarithromycin is among the most potent CYP3A4 inhibitors in clinical use (a macrolide antibiotic that irreversibly inhibits CYP3A4 by forming a stable nitrosoalkane complex with the enzyme). Co-administration of ubrogepant with a strong CYP3A4 inhibitor dramatically reduces first-pass extraction, raising ubrogepant systemic exposure to levels that may produce dose-dependent adverse effects and increase cardiovascular exposure beyond the studied range. For this reason, the prescribing information for ubrogepant lists strong CYP3A4 inhibitors (such as clarithromycin, ketoconazole, and itraconazole) as contraindicated for concomitant use. The clinically appropriate management is to withhold ubrogepant for the duration of the clarithromycin course and consider an alternative acute migraine treatment that does not share this interaction, or to await completion of the antibiotic course before using ubrogepant.

• Option A: Option A is incorrect because the mechanism of the interaction is CYP3A4 inhibition, not P-glycoprotein inhibition; while clarithromycin does also inhibit P-gp, the primary pharmacokinetic concern with ubrogepant is CYP3A4-mediated first-pass metabolism, and the combination is contraindicated rather than managed by dose escalation.
• Option C: Option C is incorrect because clarithromycin is a CYP3A4 inhibitor, not an inducer; CYP3A4 induction (which reduces ubrogepant exposure) is the effect of drugs such as rifampin, carbamazepine, and St. John's Wort, which activate PXR — clarithromycin produces the opposite effect by inhibiting CYP3A4 and raising ubrogepant exposure.
• Option D: Option D is incorrect because ubrogepant is primarily a CYP3A4 substrate, not a UGT glucuronidation substrate; UGT1A3 inhibition by clarithromycin is not the relevant pharmacokinetic mechanism, and the interaction with CYP3A4 inhibition produces elevated peak concentrations (Cmax) in addition to prolonged half-life, not merely half-life prolongation without Cmax change.
• Option E: Option E is incorrect because ubrogepant does not undergo spontaneous plasma hydrolysis; it is an orally bioavailable small molecule subject to hepatic CYP3A4 metabolism, and antibiotic effects on gut microbiota are irrelevant to its pharmacokinetic interaction with clarithromycin.

ANSWER: D

Rationale:

Rimegepant (Nurtec ODT) holds a uniquely dual regulatory approval among the gepants: it is approved for both acute migraine treatment (single 75 mg orally disintegrating tablet dose) and for preventive treatment (75 mg orally disintegrating tablet every other day). No other gepant holds both indications simultaneously under the same formulation. The every-other-day preventive schedule is consistent with the observation that regular rimegepant use reduces monthly migraine days in a manner consistent with ongoing CGRP receptor blockade reducing central sensitization over time. The orally disintegrating tablet (ODT) formulation is a practical clinical advantage: it dissolves on the tongue without water, which is particularly useful for patients who experience prominent nausea or vomiting during migraine attacks that would make conventional tablet swallowing difficult. Like all gepants, rimegepant is a CYP3A4 and P-glycoprotein substrate, and co-administration with strong CYP3A4 inhibitors is not recommended.

• Option A: Option A is incorrect because rimegepant's acute dose is a single 75 mg tablet (not 50 or 100 mg, and not for 5 consecutive days), and the preventive schedule is every other day (not twice daily); rimegepant's half-life is approximately 11 hours, not 48 hours, and the preventive mechanism reflects ongoing receptor blockade, not a half-life that maintains continuous receptor occupancy.
• Option B: Option B is incorrect on multiple counts: rimegepant's acute dose is 75 mg (not 50 or 100 mg), the preventive schedule is every other day (not once daily), and rimegepant does not inhibit CGRP synthesis — it is a receptor antagonist acting at CLR/RAMP1, not a transcriptional or biosynthetic inhibitor.
• Option C: Option C is incorrect because rimegepant is approved for both acute and preventive use; the acute indication for a single 75 mg dose was part of its original approval, and the ODT formulation does abort established migraine attacks when used acutely, as demonstrated in its pivotal trials.
• Option E: Option E is incorrect because rimegepant's preventive dose is 75 mg every other day, not 150 mg once weekly; rimegepant's half-life of approximately 11 hours does not support once-weekly dosing, and the every-other-day schedule was the regimen studied and approved in clinical trials.

ANSWER: A

Rationale:

Eptinezumab (Vyepti) is the only approved anti-CGRP monoclonal antibody administered by intravenous infusion; it is given as a 100 or 300 mg IV infusion over 30 minutes, with dosing every 3 months (quarterly). The IV route of administration achieves immediate maximal plasma concentrations at the time of infusion — there is no subcutaneous absorption phase, no depot formation, and no 3 to 7 day lag to peak concentrations. This produces immediate peripheral CGRP blockade from the moment of infusion, which has been proposed as a practical advantage for patients who arrive at their quarterly infusion appointment already experiencing or at high risk of a migraine attack, since they receive preventive drug effect at the same time as symptomatic CGRP suppression. This pharmacokinetic profile is supported by the pivotal trials PROMISE-1 (episodic migraine) and PROMISE-2 (chronic migraine), which demonstrated statistically significant reductions in monthly migraine days beginning as early as day 1 post-infusion.

• Option B: Option B is incorrect because fremanezumab is not administered intravenously; it is given subcutaneously as either 225 mg monthly or 675 mg quarterly, and anti-CGRP monoclonal antibodies do not cross the blood-brain barrier regardless of dose or route, so no IV dose achieves CSF CGRP blockade at a therapeutically meaningful level.
• Option C: Option C is incorrect because galcanezumab is not an intravenously administered agent; it is given subcutaneously as a 240 mg loading dose followed by 120 mg monthly, and neither galcanezumab nor any other anti-CGRP antibody achieves central trigeminal nucleus caudalis CGRP blockade given its exclusion from the CNS.
• Option D: Option D is incorrect because erenumab is not available in an IV formulation; it is administered only by subcutaneous injection (70 or 140 mg monthly via autoinjector or prefilled syringe), and eptinezumab — not erenumab — is the IV-administered agent in this class.
• Option E: Option E is incorrect because eptinezumab is administered intravenously, not subcutaneously; the description of a 3 to 7 day lag to peak concentrations applies to subcutaneous agents (erenumab, fremanezumab, galcanezumab) and is precisely the pharmacokinetic limitation that eptinezumab's IV route avoids.

ANSWER: C

Rationale:

Anti-CGRP monoclonal antibodies are large protein molecules of approximately 147 to 150 kDa that do not cross the intact blood-brain barrier to any clinically meaningful degree under normal conditions. Their established sites of action are peripheral: the meningeal dura mater vasculature and, critically, the trigeminal ganglion — which lies anatomically outside the blood-brain barrier in Meckel's cave and is therefore accessible to circulating antibodies. The trigeminal ganglion is a key site of CGRP storage, synthesis, and release, and its accessibility to peripherally administered biologics explains why anti-CGRP antibodies that cannot enter the CNS are nonetheless highly effective migraine preventives. Clinical trial data from all four approved monoclonal antibodies demonstrate significant reductions in monthly migraine days without CNS penetration, confirming that peripheral CGRP blockade is sufficient for therapeutic efficacy. The theoretical concern — that blocking peripheral CGRP might leave central sensitization mechanisms unaddressed, limiting efficacy — has not been validated by clinical outcomes.

• Option A: Option A is incorrect because there are no clinical trials of intrathecal or intracerebroventricular delivery of erenumab in humans; no such comparative data exist, and this option fabricates a clinical comparison that does not appear in the medical literature.
• Option B: Option B is incorrect because anti-CGRP monoclonal antibodies do not achieve clinically meaningful CSF concentrations through FcRn transcytosis; the ~0.1 to 0.3 percent CNS penetration typical of large IgG molecules is not sufficient for pharmacodynamic CGRP receptor blockade at central sites, and peripheral — not central — blockade is the established mechanism.
• Option D: Option D is incorrect because anti-CGRP monoclonal antibodies do not cross the blood-brain barrier via CGRP receptor-mediated endocytosis, the locus coeruleus is not their established site of action, and the primary mechanism is not mediated through descending pain inhibitory pathways from the locus coeruleus but through peripheral trigeminal CGRP system blockade.
• Option E: Option E is incorrect because CGRP is expressed in central neurons, including in the trigeminal nucleus caudalis, the dorsal horn of the spinal cord, and other CNS regions; the premise that CGRP is exclusively peripheral is factually wrong, though the practical therapeutic point — that peripheral blockade is sufficient — is correct.

ANSWER: E

Rationale:

Fremanezumab (Ajovy) is approved for two dosing schedules: 225 mg administered subcutaneously once monthly, or 675 mg administered subcutaneously once every 3 months (quarterly). Both schedules produce equivalent annualized migraine day reductions — the quarterly dose of 675 mg is equivalent to three consecutive monthly doses of 225 mg given together, and long-term pharmacokinetic modeling and clinical trial data from the HALO-EM (episodic migraine) and HALO-CM (chronic migraine) trials confirmed that both regimens achieve comparable total annual CGRP blockade. The clinical implication is that the choice between monthly and quarterly dosing is patient-centered: patients who value lower injection frequency (three injections per year versus twelve) can select the quarterly option without sacrificing efficacy. This flexibility is a practical adherence advantage for patients whose barriers to preventive therapy include the inconvenience of monthly clinic visits or self-injection schedules.

• Option A: Option A is incorrect because fremanezumab is in fact approved for both monthly and quarterly dosing; the quarterly 675 mg dose was approved by the FDA based on HALO trial data demonstrating equivalent annualized efficacy, not inferior efficacy.
• Option B: Option B is incorrect because the quarterly dose is 675 mg (not 450 mg), reflecting the equivalent of three monthly 225 mg doses; fremanezumab does not use a sustained-release depot formulation that extends half-life threefold — it follows standard IgG pharmacokinetics with a half-life of approximately 31 days, and the quarterly dosing simply provides a larger initial depot of antibody to cover the full 3-month interval.
• Option C: Option C is incorrect because both the monthly and quarterly schedules are approved for episodic and chronic migraine without restriction by migraine subtype; there is no evidence that quarterly dosing fails to maintain adequate CGRP blockade in chronic migraine patients, and the HALO-CM trial included the quarterly dose arm with comparable results to monthly.
• Option D: Option D is incorrect because fremanezumab is administered subcutaneously, not intravenously; the IV route of administration is the defining feature of eptinezumab (Vyepti), not fremanezumab, and fremanezumab achieves approximately 55 to 75 percent subcutaneous bioavailability consistent with other large IgG antibodies.

ANSWER: B

Rationale:

Galcanezumab (Emgality) holds a distinct FDA approval for episodic cluster headache prevention, making it the only anti-CGRP monoclonal antibody with this additional indication among the four approved agents. For the cluster headache indication, galcanezumab is dosed at 300 mg subcutaneously once monthly during the cluster period, administered as three simultaneous 100 mg injections. This is substantially higher than the 120 mg monthly maintenance dose used for migraine prevention (after a 240 mg loading dose), reflecting the hypothesis that cluster headache — which involves intense, high-frequency attacks during discrete cluster periods — may require greater CGRP pathway blockade than episodic or chronic migraine. The cluster headache indication is episodic cluster only (not chronic cluster), and dosing is administered during the active cluster period rather than as indefinite long-term prevention.

• Option A: Option A is incorrect because erenumab does not hold an FDA approval for cluster headache prevention in any formulation or dose; the cluster headache indication belongs exclusively to galcanezumab among the currently approved anti-CGRP antibodies.
• Option C: Option C is incorrect because fremanezumab does not hold a cluster headache indication, and chronic cluster headache is notably absent from the approved indications of any anti-CGRP antibody; the galcanezumab cluster headache approval is for episodic cluster only.
• Option D: Option D is incorrect because eptinezumab does not hold an FDA approval for medication overuse headache (MOH) prevention as a distinct indication; while CGRP-targeted therapies may reduce MOH risk compared to traditional preventives, no anti-CGRP antibody carries a specific MOH prevention approval from the FDA.
• Option E: Option E is incorrect because not all four anti-CGRP antibodies hold a cluster headache indication; only galcanezumab has this approval, and the cluster headache dose of 300 mg monthly differs substantially from the 120 mg monthly maintenance dose used for migraine, so dosing is not identical across indications.

ANSWER: D

Rationale:

Anti-CGRP monoclonal antibodies — erenumab, fremanezumab, galcanezumab, and eptinezumab — follow the pharmacokinetic rules that govern all therapeutic IgG antibodies. They are eliminated by proteolytic catabolism rather than hepatic CYP450 metabolism. At low antibody concentrations, target-mediated drug disposition (TMDD) via CGRP or receptor binding and subsequent internalization contributes to elimination; at higher concentrations, FcRn-mediated recycling and non-specific proteolytic degradation dominate. Because none of these elimination pathways involves CYP3A4 or any other CYP isoform, anti-CGRP monoclonal antibodies carry no pharmacokinetic drug interactions through the CYP3A4 pathway — in direct contrast to the gepants, which are CYP3A4 substrates subject to clinically significant interactions with inhibitors and inducers. Additionally, anti-CGRP antibodies are not renally eliminated by glomerular filtration or tubular secretion and do not require dose adjustments for renal impairment; they are also not subject to hepatic impairment dose adjustments in standard clinical practice. This pharmacokinetic profile makes them inherently simpler to use in patients on complex polypharmacy than the gepants.

• Option A: Option A is incorrect because anti-CGRP monoclonal antibodies are not CYP3A4 substrates at any concentration; the concept of CYP3A4 saturation at higher doses is not applicable to antibody pharmacokinetics, and the premise of the option is factually incorrect.
• Option B: Option B is incorrect because anti-CGRP monoclonal antibodies are not renally eliminated by OAT1-mediated tubular secretion; OAT1 is a transporter relevant for small-molecule drugs such as methotrexate and NSAIDs, not for large 147 to 150 kDa IgG proteins, which are too large for tubular secretion.
• Option C: Option C is incorrect because anti-CGRP monoclonal antibodies are not metabolized by intestinal CYP3A4 (this is not a mechanism for large-protein catabolism) and the reason they require parenteral administration is their susceptibility to gastrointestinal proteolysis, not intestinal CYP3A4 activity; the option correctly notes no hepatic CYP3A4 metabolism but provides a false mechanistic explanation.
• Option E: Option E is incorrect because while the mononuclear phagocyte system participates in clearance of IgG-antigen complexes at high antigen loads, this is not the primary elimination pathway for therapeutic anti-CGRP antibodies and does not create clinically significant interactions with immunosuppressants such as methotrexate through MPS activity modification.

ANSWER: A

Rationale:

Telcagepant was the first gepant to achieve clinical proof-of-concept for CGRP receptor antagonism as a class, demonstrating in phase 2 and phase 3 trials that blocking the CLR/RAMP1 receptor could abort migraine attacks with efficacy comparable to triptans but without vasoconstriction. However, telcagepant was discontinued during development when hepatotoxicity signals emerged at the higher doses required for preventive (continuous daily) use: transaminase elevations were detected in trials evaluating twice-daily preventive dosing, with exposures that exceeded the safety threshold for hepatotoxicity. This was attributed to high plasma exposures from the sustained dosing required for prevention rather than a class-wide intrinsic hepatotoxic mechanism, as the liver enzyme elevations have not been reproduced with the subsequently approved gepants (ubrogepant, rimegepant, atogepant, zavegepant) at their approved doses. Nevertheless, liver function monitoring is recommended when gepants are co-administered with potentially hepatotoxic drugs.

• Option B: Option B is incorrect because olcegepant, not telcagepant, was an intravenously administered gepant used only in early proof-of-concept studies due to its poor oral bioavailability; olcegepant's IV-only limitation was a development barrier, but telcagepant was the oral gepant that provided the clinically definitive proof-of-concept and was subsequently discontinued for hepatotoxicity rather than bioavailability reasons.
• Option C: Option C is incorrect because MK-3207 was a gepant candidate that was discontinued due to skin photosensitivity and phototoxicity signals, not cardiovascular toxicity; the preclinical coronary vasoconstriction concern with CGRP antagonism has not been clinically validated as a cause of drug discontinuation in humans at therapeutic gepant doses.
• Option D: Option D is incorrect because telcagepant was not discontinued for serotonin syndrome or for 5-HT1B cross-talk; gepants have no serotonergic activity and no 5-HT receptor affinity, and serotonin syndrome has not been reported with gepants; the discontinuation of telcagepant was due to hepatotoxicity at preventive doses.
• Option E: Option E is incorrect because atogepant was not the original gepant developed for acute migraine; atogepant was developed primarily as a preventive agent from early in its development program and was approved for the preventive indication; it was not discontinued and subsequently redeveloped, and hypertensive crises are not a recognized dose-dependent liability of gepants as a class.

ANSWER: C

Rationale:

Atogepant (Qulipta) is a CYP3A4 substrate with an oral bioavailability of approximately 44 percent, substantially higher than ubrogepant (approximately 7 percent) but still subject to meaningful CYP3A4-mediated first-pass and systemic metabolism. When a strong CYP3A4 inhibitor such as ketoconazole, clarithromycin, or itraconazole is co-administered, CYP3A4 activity is substantially reduced, causing a clinically significant increase in atogepant plasma exposure (AUC and Cmax). To avoid supratherapeutic plasma concentrations and potential dose-dependent adverse effects, the atogepant prescribing information specifies a dose reduction to 10 mg once daily in the presence of strong CYP3A4 inhibitors. Conversely, when strong CYP3A4 inducers (such as rifampin or carbamazepine) are used concomitantly, atogepant exposure is reduced and the prescribing information advises either avoiding the combination or using the 60 mg daily dose to compensate for increased metabolic clearance.

• Option A: Option A is incorrect because CYP3A4 inhibition reduces first-pass extraction (not increases it), thereby raising bioavailability and increasing plasma exposure — the appropriate response is to decrease the atogepant dose, not increase it; the proposed dose escalation to 60 mg in this scenario would compound the risk of supratherapeutic exposure.
• Option B: Option B is incorrect because atogepant is indeed a CYP3A4 substrate, not primarily a P-glycoprotein efflux substrate, and strong CYP3A4 inhibitors produce more than a 10 percent increase in atogepant exposure — the interaction is clinically significant and is explicitly addressed in the prescribing information with a dose reduction recommendation.
• Option D: Option D is incorrect because atogepant is not contraindicated with all strong CYP3A4 inhibitors; the appropriate management is a dose reduction to 10 mg once daily, not complete discontinuation; transaminase elevations have not been universally observed at the approved doses and are not a basis for mandatory cessation in the presence of CYP3A4 inhibition.
• Option E: Option E is incorrect because atogepant is not primarily renally excreted as unchanged drug; it is a CYP3A4 substrate requiring hepatic metabolism, and CYP3A4 inhibition substantially alters its plasma exposure in a clinically meaningful way that necessitates a dose adjustment per prescribing information.

ANSWER: E

Rationale:

The cardiovascular safety concern surrounding CGRP-targeted therapy is mechanistically grounded in CGRP's established physiological role beyond the trigeminal system. CGRP is expressed throughout the cardiovascular system as a potent endogenous coronary vasodilator and cardioprotective signal. It is released from perivascular trigeminal and cardiac sensory nerve terminals during myocardial ischemia, where it produces coronary vasodilation, reduces heart rate through peripheral baroreceptor sensitization, and exerts direct cardioprotective effects on cardiomyocytes through cAMP-mediated anti-apoptotic signaling. Critically, animal studies of myocardial infarction demonstrated that CGRP receptor antagonism with early gepant candidates worsened infarct size and impaired ischemic preconditioning — a preclinical signal with a clear and compelling mechanistic explanation. These data led regulatory agencies and drug developers to deliberately exclude patients with recent myocardial infarction, unstable angina, stroke within 6 months, or uncontrolled hypertension from pivotal CGRP antibody clinical trials, creating a safety database that cannot be considered definitive for the highest-risk cardiovascular population. Current American Headache Society guidance recommends avoiding anti-CGRP therapies in patients with recent major cardiovascular events and exercising clinical judgment in those with stable cardiovascular disease.

• Option A: Option A is incorrect because gepants have no 5-HT1B receptor affinity at any plasma concentration; they are pure CGRP receptor antagonists with no serotonergic activity, and the cardiovascular concern has nothing to do with 5-HT1B off-target effects, which have not been described for any approved gepant.
• Option B: Option B is incorrect because anti-CGRP monoclonal antibodies do not cross-react with natriuretic peptides or their receptors; there is no structural homology between CGRP and BNP/NT-proBNP that produces pharmacologically meaningful cross-reactivity, and natriuretic peptide receptor binding has not been identified as a mechanism of cardiovascular concern for this drug class.
• Option C: Option C is incorrect because CGRP receptor antagonism does not produce hypokalemia through renal collecting duct KATP channel effects; KATP channels in vascular smooth muscle contribute to CGRP's vasodilatory signaling, but renal potassium wasting as a consequence of CGRP blockade has not been demonstrated and is not the basis for the cardiovascular safety concern.
• Option D: Option D is incorrect because gepants do not produce QTc prolongation; CGRP receptor blockade in the cardiac conduction system is not an established mechanism of action potential duration prolongation, and no gepant has a class-wide or drug-specific QTc monitoring requirement in its prescribing information.

ANSWER: B

Rationale:

Blood pressure elevation has been observed with erenumab — specifically at the 140 mg monthly dose — in a subset of clinical trials and post-marketing reports, and this finding is mechanistically consistent with CGRP's established role as a contributor to resting vascular tone. CGRP is a tonic vasodilator in the peripheral vasculature: perivascular trigeminal and other sensory nerve terminals continuously release small amounts of CGRP that contribute to basal vasodilatory tone and help regulate resting systemic vascular resistance. Blocking CLR/RAMP1 receptors on vascular smooth muscle with erenumab — particularly at the higher 140 mg dose, which achieves greater receptor occupancy — can partially remove this tonic CGRP-mediated vasodilation, increasing peripheral vascular resistance and raising blood pressure. This effect is mild in most patients and has not driven a class-wide blood pressure monitoring mandate, but monitoring is clinically prudent for patients with pre-existing hypertension initiated on erenumab, and blood pressure management optimization before starting erenumab is recommended by headache society guidance.

• Option A: Option A is incorrect because CGRP receptor blockade does not produce tachycardia through sinoatrial node effects; while CGRP does have some chronotropic activity, erenumab-associated tachycardia is not a recognized adverse effect in clinical trials, and the mechanism proposed (unopposed sympathetic chronotropy from CGRP blockade at the SA node) is not an established pharmacological concern with erenumab.
• Option C: Option C is incorrect because erenumab-associated blood pressure elevation is not attributed to renal sodium retention through medullary CGRP receptor blockade; peripheral edema as a drug class effect and renal natriuresis impairment have not been established as mechanisms of erenumab-associated hypertension, and diuretic co-therapy is not routinely recommended for erenumab-initiated hypertension.
• Option D: Option D is incorrect because blood pressure elevation is not a class effect of all four anti-CGRP antibodies; it has been noted specifically with erenumab (and primarily at the 140 mg dose), not uniformly across fremanezumab, galcanezumab, and eptinezumab, and the proposed mechanism of mast cell degranulation and histamine-triggered sympathetic surges is not the established pharmacological explanation for this adverse effect.
• Option E: Option E is incorrect because erenumab is a highly selective antibody targeting the CLR/RAMP1 interface and does not produce meaningful cross-reactivity with CLR/RAMP2 (the adrenomedullin receptor); its epitope is specific to the assembled CLR/RAMP1 heterodimer and does not extend to the CLR/RAMP2 complex, and off-target adrenomedullin receptor blockade has not been reported as a mechanism of erenumab-associated blood pressure effects.

ANSWER: D

Rationale:

The prolonged half-life of therapeutic IgG monoclonal antibodies — approximately 27 to 31 days for the anti-CGRP antibodies, and similar across essentially all therapeutic IgG1, IgG2, and IgG4 molecules — is primarily determined by FcRn (neonatal Fc receptor)-mediated recycling. IgG molecules internalized into endosomes via pinocytosis encounter FcRn at the acidic endosomal pH (approximately 6.0), where they bind with high affinity. This binding protects the antibody from lysosomal degradation — the fate of most endocytosed proteins. The IgG-FcRn complex is then trafficked back to the cell surface, where physiological pH (approximately 7.4) reduces FcRn affinity, releasing the intact antibody back into the circulation. Without this FcRn-mediated salvage pathway, IgG molecules would have half-lives of only 1 to 2 days (consistent with FcRn-knockout animal data). This mechanism explains why all four approved anti-CGRP antibodies — despite differences in IgG subclass and target — share terminal half-lives of approximately 27 to 31 days and can be dosed monthly or quarterly.

• Option A: Option A is incorrect because the low volume of distribution of anti-CGRP antibodies (approximately 3 to 6 liters) reflects predominantly intravascular and extracellular fluid distribution, not adipose depot storage; antibodies are hydrophilic proteins that do not partition into adipose tissue, and the prolonged half-life is due to FcRn recycling rather than slow release from a lipid depot.
• Option B: Option B is incorrect because fremanezumab does not form covalent bonds with CGRP; it binds the CGRP ligand non-covalently (reversibly), and the antibody-antigen complex is dissociable; renal filtration is not the mechanism of IgG elimination since 147 to 150 kDa proteins are too large for glomerular filtration.
• Option C: Option C is incorrect because IgG elimination follows mixed-order kinetics that depend on concentration: at low antibody concentrations, target-mediated drug disposition (TMDD) contributes significantly; at higher concentrations, FcRn-mediated recycling and non-specific catabolism dominate; the elimination is not zero-order (constant-rate), and the monthly dosing interval reflects the FcRn-determined half-life rather than any zero-order kinetic property.
• Option E: Option E is incorrect because IgG antibodies are among the most hydrophilic large molecules in pharmacology — they have virtually no lipophilicity and do not partition into cell membranes or phospholipid bilayers; a logP of 4.5 would represent an extremely lipophilic small molecule, not a therapeutic antibody; there is no erythrocyte reservoir mechanism for IgG molecules.

ANSWER: A

Rationale:

Zavegepant (Zavzpret) is the first and only intranasal gepant, approved for acute migraine treatment as a single 10 mg intranasal dose. Its intranasal route of administration provides a pharmacokinetic profile specifically suited to this patient's clinical barriers. The nasal mucosal delivery bypasses gastrointestinal absorption entirely — eliminating the vulnerability to nausea-induced gastroparesis and the uncertainty of variable oral absorption during a migraine attack — and also avoids significant hepatic first-pass metabolism, achieving peak plasma concentrations within approximately 30 minutes of administration. This onset profile is faster than oral gepants (typically 1 to 2 hours to peak) and comparable to subcutaneous triptans, making zavegepant the most appropriate gepant formulation for patients with early severe nausea, rapid escalation to severe pain, or attacks where oral intake is impractical. Its metabolism involves CYP3A4 to a lesser degree than the oral gepants, and it retains the class-defining absence of vasoconstriction.

• Option B: Option B is incorrect because rimegepant ODT is an orally disintegrating tablet that dissolves on the tongue but is absorbed through the gastrointestinal mucosa rather than producing true transmucosal buccal delivery; it does not achieve peak concentrations within 15 minutes, and its onset of action is not comparable to intravenous administration — typical Tmax for rimegepant ODT is approximately 1.5 hours, far slower than the 30-minute nasal profile of zavegepant.
• Option C: Option C is incorrect because reduced gastrointestinal motility from migraine-associated nausea does not increase gepant bioavailability; gastroparesis reduces dissolution and absorption of oral medications by slowing gastric emptying and reducing drug contact with absorptive intestinal surfaces, which would reduce rather than maintain or increase ubrogepant bioavailability during a severe migraine attack with nausea.
• Option D: Option D is incorrect because atogepant is approved exclusively for migraine prevention and does not hold an acute migraine treatment indication; the 60 mg dose is not approved for acute rescue use in patients already on a preventive gepant regimen, and atogepant's onset profile during an established attack is not superior to zavegepant's intranasal pharmacokinetics.
• Option E: Option E is incorrect because gepant absorption is not mediated primarily by OAT3 or PEPT1 active transporters that are nausea-resistant; oral gepant absorption involves passive and CYP-related processes subject to gastroparesis, and the clinical reality is that nausea-induced gastric stasis significantly impairs oral drug absorption during migraine attacks — the choice of formulation (intranasal versus oral) is clinically meaningful and not reducible to CYP interaction profile alone.

ANSWER: C

Rationale:

Medication overuse headache (MOH), formerly called analgesic rebound headache, occurs when acute migraine medications are used on more than 10 to 15 days per month for more than 3 months, producing a chronification of headache through central sensitization mechanisms. Triptans carry a well-established MOH risk at more than 10 treatment days per month. Gepants, by contrast, appear to have substantially lower MOH risk based on the available clinical and post-marketing data. The most compelling evidence is the rimegepant preventive trial data: rimegepant used every other day for migraine prevention — including in patients who also use it acutely — does not produce MOH even with this frequent dosing pattern, which would clearly exceed MOH thresholds for triptans. Post-marketing surveillance for the gepant class has not established gepants as a cause of MOH in the way that triptans, opioids, barbiturates, and overused analgesics are. This low MOH risk makes gepants an attractive option for patients presenting with triptan-overuse MOH who need to reduce triptan frequency and transition to an alternative acute treatment class. Anti-CGRP monoclonal antibodies have no known MOH risk as they are preventive-only agents, not acute treatments.

• Option A: Option A is incorrect because gepants and triptans have fundamentally different mechanisms — gepants block CGRP at the receptor while triptans agonize 5-HT1B to cause vasoconstriction and reduce trigeminal transmission — and the MOH risk is not equivalent; the central sensitization leading to MOH with triptans is well-established and not reproduced with gepants at similar use frequencies.
• Option B: Option B is incorrect because gepants do not produce a CGRP rebound effect with supraphysiological CGRP levels after each dose; as competitive reversible antagonists, they simply dissociate from the receptor as plasma levels fall, without driving compensatory CGRP overproduction analogous to caffeine withdrawal; this mechanism of gepant-induced MOH has not been demonstrated in clinical or post-marketing data.
• Option D: Option D is incorrect because gepants have not been formally classified as high-MOH-risk agents by the International Headache Society; the available evidence, including the ADVANCE and PROGRESS atogepant trial data, does not support a high MOH classification for gepants, and the 30 percent transformed migraine figure cited is not derived from the ADVANCE trial data.
• Option E: Option E is incorrect because anti-CGRP monoclonal antibodies are preventive-only agents that are not administered acutely and therefore cannot by definition produce MOH through the mechanism of overuse of an acute medication; monthly preventive injections do not produce the central sensitization rebound associated with frequent acute medication dosing.

ANSWER: E

Rationale:

The receptor-versus-ligand distinction among the four approved anti-CGRP monoclonal antibodies has a clinically meaningful pharmacological rationale that supports switching between mechanisms after failure of one approach. Erenumab blocks the CLR/RAMP1 receptor; fremanezumab, galcanezumab, and eptinezumab block the CGRP ligand before it can reach the receptor. The mechanisms of pharmacodynamic escape from each strategy differ: a patient whose trigeminal system adapts to receptor blockade (through receptor upregulation, downstream signal amplification, or compensatory CGRP-independent vasodilatory pathways) may have residual responsiveness to a ligand-targeted antibody that reduces the availability of CGRP itself upstream of the receptor. Conversely, a patient who develops escape from ligand blockade (through CGRP upregulation that overwhelms antibody capture) might respond to receptor blockade that prevents even elevated CGRP from signaling. There is also evidence from real-world clinical practice that patients who fail one anti-CGRP antibody respond to a subsequent one, including across the receptor/ligand mechanistic divide. Current headache society guidance supports sequential trials of anti-CGRP antibodies after failure, and the receptor-versus-ligand distinction is one consideration in selecting the next agent.

• Option A: Option A is incorrect because the premise that identical downstream blockade makes switching futile ignores the pharmacological reality that the mechanisms of escape differ; a drug-resistant state arising from receptor-level adaptation does not necessarily confer resistance to ligand-level blockade, and real-world data document responses to second-line anti-CGRP antibodies after first-line failure.
• Option B: Option B is incorrect because no CGRP rebound phenomenon producing a 4 to 8 week severe migraine rebound period has been documented with switching from ligand-targeted to receptor-targeted anti-CGRP antibodies; stored CGRP is not excessively released upon antibody clearance, and switching between anti-CGRP antibodies is an accepted clinical practice without a contraindication based on sequencing.
• Option C: Option C is incorrect because anti-drug antibodies (ADAs) against anti-CGRP monoclonal antibodies occur but are relatively infrequent clinically meaningful neutralizing ADAs, do not universally cross-react across structurally distinct antibodies (erenumab, which targets the receptor, is structurally very different from the ligand-targeting antibodies), and do not render subsequent antibodies pharmacologically inert as a rule; ADA formation is monitored but is not a reason to avoid sequential anti-CGRP antibody trials.
• Option D: Option D is incorrect because no head-to-head trials comparing all four anti-CGRP antibodies were required before or achieved as a condition of approval; regulatory approval was based on placebo-controlled efficacy data for each agent, not on non-inferiority to competitors; and the receptor-versus-ligand distinction is pharmacologically and clinically meaningful, not merely preclinical.

ANSWER: B

Rationale:

Cortical spreading depression (CSD) is the neurophysiological correlate of the migraine aura, first described by Leão in 1944 and confirmed as the mechanism underlying the spreading visual aura through decades of subsequent human and animal research. CSD is a slowly propagating (3 to 5 mm per minute) wave of near-complete neuronal and glial depolarization characterized by massive transmembrane ion shifts — potassium efflux and sodium, calcium, and chloride influx — followed by sustained suppression of cortical electrical activity that takes several minutes to recover. As CSD spreads outward from a focus in the occipital cortex, it produces the characteristic expanding scotoma: a crescent of positive visual phenomenon (scintillation) advancing ahead of the area of suppressed cortical activity. CSD activates meningeal trigeminal C- and A-delta afferents through multiple mechanisms, including direct ionic stimulation at the cortical surface and meningeal nociceptor sensitization by inflammatory mediators generated during and after CSD, driving CGRP release from both peripheral trigeminal terminals into the dural vasculature and from central trigeminal terminals into the trigeminal nucleus caudalis. This peripheral and central CGRP release initiates the neurogenic inflammatory cascade that produces the headache phase following the aura.

• Option A: Option A is incorrect because the aura is not produced by thalamocortical gamma oscillations propagating antidromically through the optic radiations to the lateral geniculate nucleus; there are no direct lateral geniculate nucleus projections to the trigeminal nucleus caudalis, and the mechanism described does not correspond to any established neurophysiology of migraine aura.
• Option C: Option C is incorrect because migraine aura is not caused by focal cortical ischemia from platelet microaggregates; this distinction is clinically important — migraine aura expands at 3 to 5 mm per minute due to CSD, while TIA symptoms typically evolve faster and do not show the same expanding temporal pattern; the vascular platelet occlusion theory of migraine aura has been superseded by the CSD model.
• Option D: Option D is incorrect because the aura is not produced by synchronized interneuron inhibitory waves of hyperpolarization; this description reverses the actual neurophysiology of CSD, which is a depolarizing (not hyperpolarizing) wave, and inhibitory parvalbumin interneuron synchrony does not produce the trigeminal activation pathway described.
• Option E: Option E is incorrect because CSD triggers both peripheral and central CGRP release; the pial membrane does not prevent ionic and mediator-mediated communication between the cortex and overlying meninges, and the peripheral meningeal component of trigeminal CGRP release during CSD is well-established in animal studies and is considered an important contributor to the headache phase.

ANSWER: D

Rationale:

Atogepant (Qulipta) is the only approved gepant that holds exclusively a preventive indication — it has no approved acute migraine treatment indication. Its preventive evidence base spans both episodic and chronic migraine. The ADVANCE trial was a randomized, double-blind, placebo-controlled phase 3 trial in adults with episodic migraine (4 to 14 migraine days per month) that demonstrated statistically significant reductions in mean monthly migraine days at all three atogepant doses (10, 30, and 60 mg once daily) versus placebo over a 12-week treatment period. The PROGRESS trial extended this evidence to chronic migraine (15 or more headache days per month, at least 8 of which were migraine days), demonstrating comparable statistically significant efficacy with once-daily atogepant. Together, these trials established atogepant as an oral once-daily gepant preventive with a broad indication encompassing both episodic and chronic migraine populations. This profile — once-daily oral dosing, no acute indication, efficacy across both migraine subtypes — distinguishes atogepant from rimegepant (which has both acute and preventive indications) and from ubrogepant and zavegepant (which have acute-only indications).

• Option A: Option A is incorrect because rimegepant is not approved exclusively for prevention; it holds a dual indication for both acute migraine treatment (75 mg single dose) and preventive treatment (75 mg every other day); the preventive trial for rimegepant was not named ADVANCE or REGAIN — REGAIN is the galcanezumab chronic migraine trial.
• Option B: Option B is incorrect because zavegepant (Zavzpret) is approved for acute migraine treatment, not exclusively for prevention; it is an intranasal agent approved for acute use given its rapid onset, and no preventive indication has been approved for zavegepant.
• Option C: Option C is incorrect because ubrogepant is approved for acute migraine treatment, not prevention; the ACHIEVE I and ACHIEVE II trials were acute treatment trials demonstrating efficacy in freedom from pain at 2 hours, and ubrogepant does not hold a preventive indication.
• Option E: Option E is incorrect because the PROGRESS trial in chronic migraine was not discontinued due to hepatotoxicity; atogepant successfully completed the PROGRESS trial, and its approval does include chronic migraine in addition to episodic migraine; the hepatotoxicity that led to telcagepant's discontinuation has not been reproduced with atogepant at approved doses.

ANSWER: A

Rationale:

Erenumab (Aimovig) is a fully human IgG2 subclass monoclonal antibody. The IgG2 subclass was selected because it has reduced Fc receptor engagement compared to IgG1: IgG2 binds Fcγ receptors (FcγRI, FcγRII, FcγRIII) with lower affinity than IgG1, minimizing complement activation and antibody-dependent cellular cytotoxicity (ADCC). For a therapeutic antibody whose intended pharmacological function is purely receptor blockade — preventing CGRP from activating the CLR/RAMP1 receptor — there is no therapeutic benefit to complement activation or ADCC; indeed, unwanted immune effector recruitment could cause local inflammation, injection site reactions, or systemic immune responses that would limit tolerability for a long-term monthly preventive. The IgG2 subclass is therefore pharmacologically appropriate for erenumab's mechanism and its intended use as a chronic preventive agent. This subclass selection strategy is common across therapeutic antibodies designed purely for target blockade without cell-killing function. Fremanezumab uses IgG2a (another reduced-effector subclass), and galcanezumab uses IgG4, which also has reduced Fc effector function for similar reasons.

• Option B: Option B is incorrect because IgG2 does not cross the blood-brain barrier more efficiently than IgG1; no IgG subclass achieves clinically meaningful CNS penetration under normal conditions, and there is no complement receptor-mediated transcytosis pathway for IgG across the blood-brain barrier; the rationale for IgG2 selection is Fc effector function reduction, not CNS penetration.
• Option C: Option C is incorrect because IgG2 does not undergo faster renal elimination than IgG1 and does not have a half-life of approximately 14 days; anti-CGRP IgG2 antibodies including erenumab have a terminal half-life of approximately 27 days, consistent with FcRn-mediated recycling typical of all IgG subclasses, and the IgG2 subclass was not selected to tune half-life.
• Option D: Option D is incorrect because IgG2 does not form stable functional homodimers in solution that double its molecular weight; while IgG2 can form disulfide-linked half-antibody species, it does not produce a stable 300 kDa homodimer, and the rationale for its selection is not increased avidity through dimerization.
• Option E: Option E is incorrect because IgG2 does not bind FcRn at physiological pH in a way that prolongs half-life to 90 days; all IgG subclasses release from FcRn at physiological pH (approximately 7.4) — that pH-dependent release is the fundamental mechanism by which recycled antibody is released back into the circulation, and erenumab is dosed monthly (not quarterly), consistent with an approximately 27-day half-life.

ANSWER: C

Rationale:

Erenumab's somewhat higher constipation rate compared to the ligand-targeting anti-CGRP monoclonal antibodies (fremanezumab, galcanezumab, eptinezumab) is best explained by the pharmacological implications of its receptor-targeted versus ligand-targeted mechanism in the context of enteric CGRP physiology. CGRP is expressed in the enteric nervous system — specifically, beta-CGRP (from the CALCB gene) is the predominant isoform expressed in enteric neurons of the gastrointestinal tract, where CLR/RAMP1 receptors on enteric neurons modulate intestinal smooth muscle activity and peristaltic reflexes. Erenumab, by targeting the CLR/RAMP1 receptor, blocks the actions of any CGRP that reaches that receptor, regardless of isoform — including both alpha-CGRP and the enteric beta-CGRP. Ligand-targeting antibodies (fremanezumab, galcanezumab, eptinezumab) were primarily developed to capture circulating alpha-CGRP; their affinity for beta-CGRP may be somewhat lower or the local enteric CGRP concentrations may make antibody capture less complete compared to receptor blockade. The net effect is that erenumab may produce more complete enteric CGRP pathway inhibition than ligand-targeted antibodies, manifesting as a higher rate of constipation.

• Option A: Option A is incorrect because erenumab's constipation rate is not attributed to IgG2-mediated mast cell histamine release in the colonic wall; this mechanism is not established for erenumab's gastrointestinal adverse effect profile, and the constipation rate difference reflects CGRP receptor pharmacology in the enteric nervous system rather than Fcγ receptor-mast cell interactions.
• Option B: Option B is incorrect in its framing: while the logical basis it proposes (more complete CGRP blockade by receptor vs. ligand targeting) has some plausibility, the specific claim that fremanezumab and others "only capture circulating CGRP" while erenumab blocks "all CGRP from reaching the receptor" oversimplifies the pharmacodynamics and is not the established mechanistic explanation; the enteric beta-CGRP isoform distinction is the more precise pharmacological explanation.
• Option D: Option D is incorrect because subcutaneous injection into the abdominal wall does not result in peritoneal deposition of antibody or higher local enteric concentrations; subcutaneous injection delivers antibody into the interstitial space of the subcutaneous fat layer, where it is absorbed into lymphatics and the systemic circulation, not into the peritoneal cavity; injection site does not determine local enteric CGRP receptor concentrations.
• Option E: Option E is incorrect because the constipation difference between erenumab and the ligand-targeting antibodies is not due to a difference in molecular weight causing physical colonic deposition; the minor difference in molecular mass (approximately 147 to 150 kDa across the class) is not pharmacologically meaningful in terms of intestinal transit, and IgG antibodies are not excreted into the colonic lumen in amounts that affect stool transit.

ANSWER: E

Rationale:

The sensory transduction mechanism linking chemical triggers to CGRP release from trigeminal afferents involves transient receptor potential (TRP) ion channels, specifically TRPV1 (transient receptor potential vanilloid 1) and TRPA1 (transient receptor potential ankyrin 1). These channels are expressed on nociceptive small-diameter C-fibers and thinly myelinated A-delta fibers of the trigeminal ganglion — the same neurons that contain CGRP in dense-core vesicles and project to the meningeal dura mater and cerebral vasculature. TRPV1 responds to capsaicin, heat above 43°C, acidic pH, and endocannabinoids; TRPA1 responds to a wide range of reactive environmental chemicals, including acrolein (in diesel exhaust and cigarette smoke), allyl isothiocyanate (mustard), and endogenous reactive oxygen species and inflammatory lipids. Bradykinin and prostaglandins — inflammatory mediators generated in sensitized meningeal tissue — sensitize TRPV1 and TRPA1 to reduce their activation threshold, explaining the phenomenon of central sensitization and allodynia in established migraine. When environmental chemicals (including potent odorants reaching the olfactory and trigeminal branches) activate these TRP channels, sodium and calcium influx depolarizes the terminal and triggers CGRP exocytosis from dense-core vesicles into the perivascular dural space, initiating the trigeminovascular cascade.

• Option A: Option A is incorrect because Nav1.7 channels are voltage-gated sodium channels that propagate action potentials but are not the primary chemical sensor that transduces odor or inflammatory stimuli into membrane depolarization on trigeminal terminals; odorant-triggered Nav1.7 activation via an allosteric domain IV voltage sensor site is not an established mechanism for CGRP release in the trigeminovascular system.
• Option B: Option B is incorrect because ionotropic NMDA receptors on trigeminal C-fiber peripheral terminals are not the primary transduction channel for environmental chemical triggers driving CGRP release; NMDA receptors play important roles in central sensitization at the trigeminal nucleus caudalis but are not the established sensor for odor or chemical triggers at peripheral meningeal nociceptor terminals.
• Option C: Option C is incorrect because while P2X3 purinergic receptors are expressed on some trigeminal afferents and contribute to nociception, they are not the primary channel linking odorant exposure to CGRP release; ATP-driven P2X3 signaling is more relevant to headache triggered by local tissue injury or ischemia rather than the odorant/environmental chemical trigger mechanism described in this patient.
• Option D: Option D is incorrect because alpha-1 adrenergic receptors on trigeminal C-fiber terminals are not a recognized sensory transduction mechanism for odorant or chemical triggers; while the sympathetic nervous system can influence nociception, the emotional stress hypothesis of adrenergic-mediated CGRP release does not account for the direct chemical activation of trigeminal terminals by environmental odors through a receptor mechanism that bypasses TRP channels.

ANSWER: B

Rationale:

Subcutaneous administration of therapeutic monoclonal antibodies, including the anti-CGRP antibodies, is characterized by a bioavailability of approximately 50 to 80 percent and a time to peak plasma concentration (Tmax) of approximately 3 to 7 days. The reduced bioavailability (compared to 100 percent for IV) reflects incomplete local absorption and some degradation at the injection site, but is sufficient for therapeutic effect. The prolonged Tmax is explained by the rate-limiting step of lymphatic absorption: large proteins (~147 to 150 kDa) cannot cross directly into blood capillaries through tight intercellular junctions. Instead, they are taken up by initial lymphatic capillaries — which have much larger interendothelial pores — and drain through the lymphatic network (regional lymph nodes, thoracic duct) before entering the systemic venous circulation. This lymphatic absorption pathway is intrinsically slow, producing the 3 to 7 day lag to peak plasma concentrations observed for all subcutaneous monoclonal antibodies. The galcanezumab loading dose (240 mg) rapidly increases CGRP pathway blockade toward therapeutic levels by providing approximately double the monthly maintenance dose, compensating for the slow buildup that would otherwise occur with 120 mg alone; without the loading dose, steady-state therapeutic concentrations would take several months to achieve.

• Option A: Option A is incorrect because subcutaneous bioavailability is not 95 to 100 percent for IgG antibodies; it ranges approximately 50 to 80 percent due to local degradation and incomplete absorption, and the 3 to 7 day Tmax reflects lymphatic absorption kinetics, not merely the time for lymphatic drainage of a fully absorbed antibody.
• Option C: Option C is incorrect because subcutaneous bioavailability for anti-CGRP antibodies is not 5 to 15 percent; while proteases are present in subcutaneous tissue, they do not degrade the majority of subcutaneously injected IgG, and bioavailability of 50 to 80 percent is well-documented in the prescribing information for this class.
• Option D: Option D is incorrect because peak concentrations for subcutaneous IgG are not achieved within 2 to 4 hours; this Tmax is more consistent with oral small-molecule absorption; subcutaneous IgG Tmax of 3 to 7 days reflects lymphatic uptake kinetics, and large proteins are excluded from direct capillary absorption precisely because of their high molecular weight, not facilitated by it.
• Option E: Option E is incorrect because approved anti-CGRP monoclonal antibodies do not require co-formulation with recombinant hyaluronidase to achieve subcutaneous bioavailability; subcutaneous IgG absorption through lymphatics occurs without hyaluronidase, achieving the 50 to 80 percent bioavailability described; hyaluronidase co-formulation is used with some biologics (such as subcutaneous trastuzumab and rituximab) to enable high-volume rapid subcutaneous injection but is not a requirement for the anti-CGRP antibodies as currently approved.

ANSWER: D

Rationale:

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerotic arterial disease involving the peripheral circulation, characterized by arterial narrowing, reduced perfusion reserve, and a vasculature with compromised ability to dilate. Triptans are 5-HT1B/1D receptor agonists, and 5-HT1B receptor activation on vascular smooth muscle produces direct arterial vasoconstriction in both coronary and peripheral vessels. In a patient with PAD, triptan-induced vasoconstriction superimposed on already-compromised peripheral perfusion creates a risk of worsening ischemia in affected limbs or in the coronary circulation if concomitant coronary artery disease exists. The prescribing information for triptans lists peripheral vascular disease (including ischemic bowel disease) alongside ischemic heart disease and stroke as contraindications. Gepants, as competitive antagonists at the CLR/RAMP1 CGRP receptor, produce no vasoconstriction of any kind — they block CGRP-mediated vasodilation without activating any vasoconstrictor receptor — and are appropriate for acute migraine treatment in patients with peripheral vascular disease, coronary artery disease, prior stroke, and other conditions that contraindicate triptans.

• Option A: Option A is incorrect because triptans do not produce platelet activation through 5-HT2A agonism; triptans are 5-HT1B/1D agonists, not 5-HT2A agonists, and the cardiovascular contraindication to triptans in vascular disease is based on their 5-HT1B-mediated vasoconstriction, not on platelet activation; there is no established pharmacokinetic interaction between triptans and antiplatelet agents at the platelet level.
• Option B: Option B is incorrect because triptans do not inhibit CYP2C19 in a clinically meaningful way that reduces clopidogrel bioactivation; sumatriptan and most other triptans are metabolized by MAO-A rather than CYP2C19, and competitive CYP2C19 inhibition reducing clopidogrel efficacy is not a recognized triptan drug interaction.
• Option C: Option C is incorrect because triptans do not produce venous thromboembolism through 5-HT1B receptor-mediated venous valve endothelial activation; this mechanism is not established for triptans, and the contraindication of triptans in PAD is based on arterial vasoconstriction in the peripheral and coronary circulation, not on venous thrombotic risk.
• Option E: Option E is incorrect because there is no specific guideline or regulatory restriction prohibiting triptans within 12 months of coronary stent placement due to in-stent thrombosis; the basis for triptan contraindication in post-stent patients is coronary artery disease per se (5-HT1B-mediated vasoconstriction in compromised coronary vessels), not a stent-specific thrombosis mechanism, and the 12-month peri-stent restriction described is not a recognized clinical standard.

ANSWER: A

Rationale:

Eptinezumab (Vyepti) is unique among the four approved anti-CGRP monoclonal antibodies in demonstrating measurable migraine prevention beginning as early as day 1 following its first administration. This early-onset efficacy was demonstrated in the PROMISE-1 trial (episodic migraine) and the PROMISE-2 trial (chronic migraine), where the proportion of patients experiencing migraine on day 1 post-infusion was significantly lower in eptinezumab-treated patients compared to placebo. The pharmacokinetic explanation is direct: eptinezumab is administered as a 30-minute intravenous infusion of 100 or 300 mg. The IV route produces immediate maximal plasma concentrations at the time of infusion completion — there is no absorption phase, no subcutaneous depot formation, and no 3 to 7 day lag to Tmax that characterizes subcutaneous antibodies (erenumab, fremanezumab, galcanezumab). This immediate peak systemic exposure translates to immediate peripheral CGRP blockade at meningeal trigeminal terminals and at the trigeminal ganglion, both sites of CGRP pathway pharmacological relevance. The clinical implication is the practical advantage noted in the module: patients who are experiencing or are at high risk of a migraine attack at the time of their quarterly infusion appointment receive concurrent acute CGRP suppression and preventive dosing from the moment of infusion.

• Option B: Option B is incorrect because erenumab does not achieve day 1 prevention onset and its STRIVE and LIBERTY trials did not demonstrate day 1 efficacy; IgG2 does not have faster subcutaneous absorption than IgG1 — both subclasses rely on lymphatic absorption with a 3 to 7 day Tmax; the day 1 advantage belongs specifically to eptinezumab by virtue of its IV route.
• Option C: Option C is incorrect because fremanezumab did not demonstrate day 1 efficacy in HALO-EM and HALO-CM — these trials showed prevention developing over the first weeks of therapy, consistent with the 3 to 7 day Tmax of subcutaneous antibodies; the sub-picomolar affinity mechanism proposed is speculative and does not correspond to the established pharmacokinetics of fremanezumab's subcutaneous absorption.
• Option D: Option D is incorrect because galcanezumab did not demonstrate day 1 prevention onset and its EVOLVE-1 and EVOLVE-2 trials did not show day 1 efficacy; the IgG4 Fab-arm exchange mechanism producing monovalent bispecific antibodies does not enhance speed of onset by blocking membrane-bound CGRP before release — this is not an established mechanism for galcanezumab.
• Option E: Option E is incorrect because PROMISE-1 and PROMISE-2 did demonstrate early-onset efficacy at both the 100 mg and 300 mg doses; the day 1 efficacy was not exclusively a 300 mg dose effect, and there is no pharmacokinetic basis for the 100 mg dose requiring a 3 to 7 day redistribution period while the 300 mg dose achieves immediate onset — both doses achieve immediate maximal Cmax by IV administration.